【亚宝YABAO是哪个国家的品牌？】

始于1978年，山西省著名商标，主打中西药制剂/原料药和药用包装材料，致力于老年慢性病用药和妇女儿童用药，集研发、生产、销售和中药材种植于一体的企业

亚宝药业集团股份有限公司。集研发、生产、销售和中药材种植于一体，下设21个分子公司，资产总额42.5亿元，年销售收入20多亿元，员工5600余人。

公司在北京、上海、太原、成都、贵阳、运城等地建有9大生产基地， 3大研究基地，2大中药材种植基地。9大生产基地全部通过国家新版GMP认证，其中，北京生物制药通过了美国FDA cGMP认证，三分公司通过了欧盟GMP认证。

主要产品有中西药制剂、原料药和药用包装材料等共计300多个品种，主要为老年慢性病用药和妇女儿童用药。

公司拥有一支国际化的专业研发队伍，各类研发人员总计410人，其中博士22人，硕士150人。在新药的申报、生产、销售上，同国际接轨，迈出了“一地研发，三地申报；一地生产，三地销售” 的国际化步伐。

现有各类营销人员3000多人，建立了商务渠道、OTC零售、基层终端、医院招商、OTC招商、原料药、拓展销售、北京生物、保健消费品等专业的营销队伍。公司拥有完善的销售网络，销售网点覆盖全国32个省市的一、二、三级及终端市场，遍及661个市区县。

“十三五”期间，亚宝药业要“以医药为主体，以健康产品和医疗服务为两翼”，一方面深耕产业，另一方面借力资本。通过内生式的“资产经营”和外延式的“资本运作”两轮驱动，促进企业的发展。通过创建5大中心，搭建10大体系，打造6种能力，实现6种转型。

英文翻译：Started in 1978, it is a famous trademark of Shanxi Province, mainly focusing on Chinese and Western medicine preparations / APIs and pharmaceutical packaging materials. It is committed to the elderly chronic disease medication and women and children's medication. It is an enterprise of Yabao Pharmaceutical Group Co., Ltd., which integrates R & D, production, sales and Chinese medicine planting. It integrates R & D, production, sales and traditional Chinese medicine planting. It has 21 subsidiaries with total assets of 4.25 billion yuan, annual sales revenue of more than 2 billion yuan and more than 5600 employees. In Beijing, Shanghai, Taiyuan, Chengdu, Guiyang, Yuncheng and other places, the company has 9 production bases, 3 research bases and 2 large and medium-sized medicine planting bases. All the nine production bases have passed the new GMP certification of China, among which Beijing biopharmaceutical has passed the fdacgmp certification of the United States and three branches have passed the GMP certification of the European Union. The main products include more than 300 varieties of Chinese and Western medicine preparations, APIs and pharmaceutical packaging materials, mainly for the elderly, chronic diseases and women and children. The company has an international professional R & D team with 410 R & D personnel, including 22 doctors and 150 masters. In terms of the application, production and sales of new drugs, we have taken the international step of "one place for research and development, three places for application, one place for production and three places for sales". At present, there are more than 3000 marketing personnel of all kinds, and a professional marketing team has been established, including business channels, OTC retail, grassroots terminals, hospital investment, OTC investment, API, sales expansion, Beijing biology, health care consumer goods, etc. The company has a complete sales network, with sales outlets covering the first, second, third level and terminal markets of 32 provinces and cities nationwide, covering 661 cities, districts and counties. During the 13th Five Year Plan period, Yabao pharmaceutical industry should "take medicine as the main body, health products and medical services as the two wings". On the one hand, Yabao pharmaceutical industry should deepen its industry, on the other hand, it should borrow capital. Through the endogenous "asset management" and the extended "capital operation" two-wheel drive, to promote the development of enterprises. By creating 5 centers, building 10 systems, building 6 capabilities, and realizing 6 transformations.

本文链接： https://www.waitui.com/brand/f806b0208.html 联系电话：0359-3388114,400-1380-600